SCHEMBL20768139

SCHEMBL20768139

CC(C)c1c(C(=O)O)cnc2c(-c3ccc(F)c(F)c3)c(Cl)nn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ AKR1C3 P42330 1/20 0.37
▸ AKR1C2 P52895 1/20 0.37
▸ GRIN2B Q13224 4/20 0.36
▸ DHODH Q02127 3/20 0.35
▸ KMO O15229 2/20 0.34
▸ GRIN1 Q05586 3/20 0.33
▸ THRB P10828 2/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ PDE5A O76074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28619820 0.88 MAPT (0.38) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL28618955 0.88 AKR1C3 (0.37) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL20782378 0.88 MAPT (0.44) KDM4ELMNAMAPTHPGDALDH1A1
SCHEMBL20768159 0.86 ALDH1A1 (0.51) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL19464071 0.86 PPARA (0.39) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL28623625 0.81 MAPT (0.34) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL19463318 0.80 DHODH (0.37) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL28621763 0.77 CSNK1D (0.39) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL28620031 0.77 DCLRE1B (0.43) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL22280894 0.76 KDM4E (0.57) KDM4ELMNAMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
CN-109071545-B Novel pyrazolopyrimidine derivatives 拜耳动物保健有限责任公司 2021-08-03 — — CN disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-10604525-B2 Pyrazolopyrimidine derivatives BAYAL ANIMAL HEALTH GMBH (DE) 2020-03-31 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604525-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1438/4885LMNA 2671/4885MAPT 4497/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1445/4885LMNA 2619/4885MAPT 4495/4885
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1438/4885LMNA 2671/4885MAPT 4497/4885
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1445/4885LMNA 2619/4885MAPT 4495/4885
US-10934301-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 KDM4E 1445/4885LMNA 2619/4885MAPT 4495/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 KDM4E 1658/4885LMNA 3036/4885MAPT 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback